Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia PR Newswire LONDON and MOSCOW, September 11, 2012 LONDON and MOSCOW, September 11, 2012 /PRNewswire/ -- Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre- clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The results of these trials are of great importance as these novel long-acting, subcutaneous blood factors are expected to revolutionise the treatment paradigm for haemophilia sufferers worldwide. The availability of PBB's subcutaneous blood factors would make self-administration by patients at home much easier leading to a significant improvement in treatment compliance and reduction in healthcare system costs by avoiding the need for regular IV infusions. Key findings from the 8 trials with 6 products conducted at the University of Alabama were: PBB's current subcutaneous form of FVIIa achieved up to 3 days of haemostatic cover providing the prospect of sustained prophylactic treatment for haemophilia A patients who suffer an immune response to FVIII meaning that FVIII is no longer a viable therapy for them.